Qualigen Therapeutics Stock Forecast, Price & News

Qualigen Therapeutics (NASDAQ:QLGN) Frequently Asked Questions

Is Qualigen Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Qualigen Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Qualigen Therapeutics stock.
View analyst ratings for Qualigen Therapeutics or view top-rated stocks.

When is Qualigen Therapeutics' next earnings date?

Qualigen Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Qualigen Therapeutics.

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.10. The business earned $1.16 million during the quarter, compared to analyst estimates of $1.50 million.
View Qualigen Therapeutics' earnings history.

What price target have analysts set for QLGN?

1 analysts have issued 12 month price targets for Qualigen Therapeutics' stock. Their forecasts range from $6.50 to $6.50. On average, they anticipate Qualigen Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 450.8% from the stock's current price.
View analysts' price targets for Qualigen Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Qualigen Therapeutics' key executives?

Qualigen Therapeutics' management team includes the following people:

• Michael S. Poirier, Chairman, President & Chief Executive Officer
• Shishir K. Sinha, Chief Operating Officer, Secretary & VP
• Christopher L. Lotz, Chief Financial Officer & Vice President
• Wajdi Abdul-Ahad, Chief Scientific Officer & Vice President-R&D
• Tariq Arshad, Chief Medical Officer & Senior Vice President

Who are some of Qualigen Therapeutics' key competitors?

Some companies that are related to Qualigen Therapeutics include NexImmune (NEXI), OptiNose (OPTN), Zynerba Pharmaceuticals (ZYNE), Xeris Pharmaceuticals (XERS), Oncternal Therapeutics (ONCT), BioVie (BIVI), Equillium (EQ), Vascular Biogenics (VBLT), NuCana (NCNA), ProMetic Life Sciences (PFSCF), Tyme Technologies (TYME), Palatin Technologies (PTN), Atreca (BCEL), Clever Leaves (CLVR) and RedHill Biopharma (RDHL).
View all of QLGN's competitors.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Blockchain (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH).

What is Qualigen Therapeutics' stock symbol?

Qualigen Therapeutics trades on the NASDAQ under the ticker symbol "QLGN."

Who are Qualigen Therapeutics' major shareholders?

Qualigen Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.76%), Franklin Resources Inc. (0.28%), GSA Capital Partners LLP (0.27%) and Hatton Consulting Inc. (0.09%). Company insiders that own Qualigen Therapeutics stock include Amy S Broidrick, Christopher L Lotz, Kurt H Kruger, Kurt H Kruger and Michael S Poirier.
View institutional ownership trends for Qualigen Therapeutics.

Which major investors are selling Qualigen Therapeutics stock?

QLGN stock was sold by a variety of institutional investors in the last quarter, including Hatton Consulting Inc..
View insider buying and selling activity for Qualigen Therapeutics or view top insider-selling stocks.

Which major investors are buying Qualigen Therapeutics stock?

QLGN stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., GSA Capital Partners LLP, and Geode Capital Management LLC. Company insiders that have bought Qualigen Therapeutics stock in the last two years include Amy S Broidrick, Christopher L Lotz, Kurt H Kruger, and Michael S Poirier.
View insider buying and selling activity for Qualigen Therapeutics or or view top insider-buying stocks.

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qualigen Therapeutics' stock price today?

One share of QLGN stock can currently be purchased for approximately $1.18.

How much money does Qualigen Therapeutics make?

Qualigen Therapeutics has a market capitalization of $34.36 million.

How many employees does Qualigen Therapeutics have?

Qualigen Therapeutics employs 36 workers across the globe.

What is Qualigen Therapeutics' official website?

The official website for Qualigen Therapeutics is www.qualigeninc.com.

Where are Qualigen Therapeutics' headquarters?

Qualigen Therapeutics is headquartered at 2042 Corte Del Nogal, Carlsbad CA, 92011.

How can I contact Qualigen Therapeutics?

Qualigen Therapeutics' mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. The company can be reached via phone at (310) 203-1000 or via email at [email protected].